{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T02:03:08Z","timestamp":1779760988297,"version":"3.53.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"vor","delay-in-days":42,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004156","name":"Mahidol University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004156","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"DOI":"10.1186\/s12882-026-04980-4","type":"journal-article","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T02:48:00Z","timestamp":1776134880000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost-utility analysis of sodium-glucose cotransporter-2 inhibitors on chronic kidney disease progression in patients with type 2 diabetes mellitus"],"prefix":"10.1186","volume":"27","author":[{"given":"Sukanya","family":"Siriyotha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amarit","family":"Tansawet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oraluck","family":"Pattanaprateep","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanawan","family":"Kongmalai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panu","family":"Looareesuwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junwei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suparee W.","family":"Boonmanunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gareth J.","family":"McKay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Attia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ammarin","family":"Thakkinstian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,14]]},"reference":[{"issue":"11","key":"4980_CR1","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1161\/CIRCRESAHA.115.306884","volume":"118","author":"JA Beckman","year":"2016","unstructured":"Beckman JA, Creager MA. Vascular Complications of Diabetes. Circul Res. 2016;118(11):1771\u201385.","journal-title":"Circul Res"},{"issue":"9981","key":"4980_CR2","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1016\/S0140-6736(14)61601-9","volume":"385","author":"T Liyanage","year":"2015","unstructured":"Liyanage T, Ninomiya T, Jha V, Neal B, Patrice HM, Okpechi I, et al. Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet. 2015;385(9981):1975\u201382.","journal-title":"Lancet"},{"key":"4980_CR3","unstructured":"Nephrology ISo. Global Kidney Health Atlas 2023. Available from: https:\/\/www.theisn.org\/initiatives\/global-kidney-health-atlas\/"},{"issue":"4","key":"4980_CR4","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1515920","volume":"375","author":"C Wanner","year":"2016","unstructured":"Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, et al. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med. 2016;375(4):323\u201334.","journal-title":"N Engl J Med"},{"issue":"7","key":"4980_CR5","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017;377(7):644\u201357.","journal-title":"N Engl J Med"},{"issue":"24","key":"4980_CR6","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019;380(24):2295\u2013306.","journal-title":"N Engl J Med"},{"issue":"15","key":"4980_CR7","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020;383(15):1436\u201346.","journal-title":"N Engl J Med"},{"issue":"2","key":"4980_CR8","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"Empagliflozin in Patients with Chronic Kidney Disease","year":"2023","unstructured":"Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2023;388(2):117\u201327.","journal-title":"N Engl J Med"},{"issue":"1","key":"4980_CR9","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S2213-8587(19)30384-5","volume":"8","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Karasik A, Thuresson M, Melzer-Cohen C, Chodick G, Khunti K, et al. Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study. Lancet Diabetes Endocrinol. 2020;8(1):27\u201335.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"4980_CR10","doi-asserted-by":"publisher","first-page":"m1186","DOI":"10.1136\/bmj.m1186","volume":"369","author":"B Pasternak","year":"2020","unstructured":"Pasternak B, Wintzell V, Melbye M, Eliasson B, Svensson AM, Franz\u00e9n S, et al. Use of sodium-glucose co-transporter 2 inhibitors and risk of serious renal events: Scandinavian cohort study. BMJ. 2020;369:m1186.","journal-title":"BMJ"},{"issue":"1","key":"4980_CR11","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/s12933-021-01396-2","volume":"20","author":"FJ Lin","year":"2021","unstructured":"Lin FJ, Wang CC, Hsu CN, Yang CY, Wang CY, Ou HT. Renoprotective effect of SGLT-2 inhibitors among type 2 diabetes patients with different baseline kidney function: a multi-center study. Cardiovasc Diabetol. 2021;20(1):203.","journal-title":"Cardiovasc Diabetol"},{"issue":"11","key":"4980_CR12","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.2337\/dc20-1890","volume":"43","author":"Y Xie","year":"2020","unstructured":"Xie Y, Bowe B, Gibson AK, McGill JB, Maddukuri G, Yan Y, et al. Comparative Effectiveness of SGLT2 Inhibitors, GLP-1 Receptor Agonists, DPP-4 Inhibitors, and Sulfonylureas on Risk of Kidney Outcomes: Emulation of a Target Trial Using Health Care Databases. Diabetes Care. 2020;43(11):2859\u201369.","journal-title":"Diabetes Care"},{"issue":"1","key":"4980_CR13","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1186\/s12933-022-01641-2","volume":"21","author":"S Siriyotha","year":"2022","unstructured":"Siriyotha S, Lukkunaprasit T, Looareesuwan P, Nimitphong H, McKay GJ, Attia J, et al. Effects of second-line antihyperglycemic drugs on the risk of chronic kidney disease: applying a target trial approach to a hospital-based cohort of Thai patients with type 2 diabetes. Cardiovasc Diabetol. 2022;21(1):248.","journal-title":"Cardiovasc Diabetol"},{"issue":"Supplement1","key":"4980_CR14","first-page":"S191","volume":"46","author":"NA ElSayed","year":"2022","unstructured":"ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes\u20142023. Diabetes Care. 2022;46(Supplement1):S191\u2013202.","journal-title":"Diabetes Care"},{"issue":"1","key":"4980_CR15","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1186\/s13098-024-01522-6","volume":"16","author":"A Tansawet","year":"2024","unstructured":"Tansawet A, Looareesuwan P, Teza H, Boongird S, McKay GJ, Attia J, et al. Effects of sodium-glucose cotransporter-2 inhibitors on chronic kidney disease progression: a multi-state survival model. Diabetol Metab Syndr. 2024;16(1):281.","journal-title":"Diabetol Metab Syndr"},{"issue":"6","key":"4980_CR16","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1053\/j.ajkd.2021.09.014","volume":"79","author":"OS Reifsnider","year":"2022","unstructured":"Reifsnider OS, Kansal AR, Wanner C, Pfarr E, Koitka-Weber A, Brand SB, et al. Cost-Effectiveness of Empagliflozin in Patients With Diabetic Kidney Disease in the United States: Findings Based on the EMPA-REG OUTCOME Trial. Am J Kidney Dis. 2022;79(6):796\u2013806.","journal-title":"Am J Kidney Dis"},{"issue":"12","key":"4980_CR17","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1253\/circj.CJ-22-0086","volume":"86","author":"S Kodera","year":"2022","unstructured":"Kodera S, Morita H, Nishi H, Takeda N, Ando J, Komuro I. Cost-Effectiveness of Dapagliflozin for Chronic Kidney Disease in Japan. Circ J. 2022;86(12):2021\u20138.","journal-title":"Circ J"},{"issue":"12","key":"4980_CR18","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.2215\/CJN.03790322","volume":"17","author":"P McEwan","year":"2022","unstructured":"McEwan P, Darlington O, Miller R, McMurray JJV, Wheeler DC, Heerspink HJL, et al. Cost-Effectiveness of Dapagliflozin as a Treatment for Chronic Kidney Disease: A Health-Economic Analysis of DAPA-CKD. Clin J Am Soc Nephrol. 2022;17(12):1730\u201341.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"4980_CR19","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1007\/s12325-021-02037-6","volume":"39","author":"K Vareesangthip","year":"2022","unstructured":"Vareesangthip K, Deerochanawong C, Thongsuk D, Pojchaijongdee N, Permsuwan U. Cost\u2013Utility Analysis of Dapagliflozin as an Add-on to Standard of Care for Patients with Chronic Kidney Disease in Thailand. Adv Therapy. 2022;39(3):1279\u201392.","journal-title":"Adv Therapy"},{"issue":"1","key":"4980_CR20","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1080\/13696998.2024.2368990","volume":"27","author":"L Varghese","year":"2024","unstructured":"Varghese L, Chang PW, Juntarasiripas S, Pham H, Uster A. Cost-effectiveness of add-on empagliflozin versus standard of care in management of CKD in Malaysia, Thailand and Vietnam - findings from a modelling study assessing an EMPA-KIDNEY eligible population, using CKD progression model. J Med Econ. 2024;27(1):836\u201348.","journal-title":"J Med Econ"},{"issue":"1","key":"4980_CR21","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1080\/13696998.2024.2357041","volume":"27","author":"M Ramos","year":"2024","unstructured":"Ramos M, Gerlier L, Uster A, Muttram L, Frankel AH, Lamotte M. Cost-effectiveness of empagliflozin as add-on to standard of care for chronic kidney disease management in the United Kingdom. J Med Econ. 2024;27(1):777\u201385.","journal-title":"J Med Econ"},{"key":"4980_CR22","unstructured":"Health Intervention and Technology Assessment Program Foundation MoPH. Standard Cost List for Health Technology Assessment [Available from: https:\/\/costingmenu.hitap.net"},{"key":"4980_CR23","unstructured":"Thailand Bo. Foreign Exchange Rates [Available from: https:\/\/www.bot.or.th\/english\/_layouts\/application\/exchangerate\/exchange"},{"key":"4980_CR24","unstructured":"Trade Policy and Strategy Office MoC. Consumer Price Index [Available from: https:\/\/www.price.moc.go.th\/price\/cpi\/index_new_all.asp"},{"issue":"5","key":"4980_CR25","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1080\/14737167.2018.1494574","volume":"18","author":"J Pattanaphesaj","year":"2018","unstructured":"Pattanaphesaj J, Thavorncharoensap M, Ramos-Go\u00f1i JM, Tongsiri S, Ingsrisawang L, Teerawattananon Y. The EQ-5D-5L Valuation study in Thailand. Expert Rev Pharmacoecon Outcomes Res. 2018;18(5):551\u20138.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"1","key":"4980_CR26","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/s41598-024-81747-7","volume":"15","author":"N Chitpim","year":"2025","unstructured":"Chitpim N, Leelahavarong P, Prawjaeng J, Ittiphisit S, Srinonprasert V, Kongmalai T. A cost-utility analysis of adding SGLT2 inhibitors for the management of type 2 diabetes with chronic kidney disease in Thailand. Sci Rep. 2025;15(1):249.","journal-title":"Sci Rep"},{"key":"4980_CR27","unstructured":"Guideline Development Working Group. Guideline for Health Technology Assessment in Thailand Updated Edition: 2019. [Available from: https:\/\/kb.hsri.or.th\/dspace\/handle\/11228\/5320"},{"key":"4980_CR28","unstructured":"T P. TreeAge Pro. 2024."},{"issue":"13","key":"4980_CR29","doi-asserted-by":"publisher","first-page":"3380","DOI":"10.1007\/s11606-021-07311-5","volume":"37","author":"RL Tisdale","year":"2022","unstructured":"Tisdale RL, Cusick MM, Aluri KZ, Handley TJ, Joyner AKC, Salomon JA, et al. Cost-Effectiveness of Dapagliflozin for Non-diabetic Chronic Kidney Disease. J Gen Intern Med. 2022;37(13):3380\u20137.","journal-title":"J Gen Intern Med"},{"issue":"1","key":"4980_CR30","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1080\/13696998.2023.2174749","volume":"26","author":"A Swidan","year":"2023","unstructured":"Swidan A, Elsisi GH, Ibrahim MM, Aljazzar M, Tawfik Sallam H. Projecting the potential cost-effectiveness of dapagliflozin for chronic kidney disease in Kuwait. J Med Econ. 2023;26(1):271\u201382.","journal-title":"J Med Econ"},{"issue":"2","key":"4980_CR31","doi-asserted-by":"publisher","first-page":"sfae025","DOI":"10.1093\/ckj\/sfae025","volume":"17","author":"P McEwan","year":"2024","unstructured":"McEwan P, Davis JA, Gabb PD, Wheeler DC, Rossing P, Chertow GM, et al. Dapagliflozin in chronic kidney disease: cost-effectiveness beyond the DAPA-CKD trial. Clin Kidney J. 2024;17(2):sfae025.","journal-title":"Clin Kidney J"},{"issue":"3","key":"4980_CR32","doi-asserted-by":"publisher","first-page":"e0296067","DOI":"10.1371\/journal.pone.0296067","volume":"19","author":"SK Lim","year":"2024","unstructured":"Lim SK, Lee SWH. Cost-effectiveness analysis of dapagliflozin for people with chronic kidney disease in Malaysia. PLoS ONE. 2024;19(3):e0296067.","journal-title":"PLoS ONE"},{"issue":"10","key":"4980_CR33","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1080\/14737167.2024.2382976","volume":"24","author":"P Lasalvia","year":"2024","unstructured":"Lasalvia P, V\u00e1squez ME, Arango \u00c1lvarez JJ, Garcia-Padilla P. Cost-effectiveness of dapagliflozin plus standard treatment compared to standard therapy for the management of chronic kidney disease in Colombia. Expert Rev Pharmacoecon Outcomes Res. 2024;24(10):1133\u201343.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"11","key":"4980_CR34","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1007\/s40261-024-01398-4","volume":"44","author":"H Groyer","year":"2024","unstructured":"Groyer H, Supiot R, Tardu J, Virely N, Sivignon M, San D, et al. Cost-Effectiveness of Empagliflozin (JARDIANCE(\u00ae)) in the Treatment of Patients with Chronic Kidney Disease in France, Based on the EMPA-KIDNEY Clinical Trial. Clin Drug Investig. 2024;44(11):811\u201328.","journal-title":"Clin Drug Investig"},{"issue":"12","key":"4980_CR35","doi-asserted-by":"publisher","first-page":"5546","DOI":"10.1111\/dom.15832","volume":"26","author":"K Maruyama-Sakurai","year":"2024","unstructured":"Maruyama-Sakurai K, Tachimori H, Saito E, Kohsaka S, Segawa Y, Miyata H, et al. Cost-effectiveness of sodium-glucose cotransporter-2 inhibitors in the treatment of diabetic nephropathy in Japan. Diabetes Obes Metab. 2024;26(12):5546\u201355.","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"4980_CR36","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1080\/13696998.2016.1238386","volume":"20","author":"U Permsuwan","year":"2017","unstructured":"Permsuwan U, Dilokthornsakul P, Thavorn K, Saokaew S, Chaiyakunapruk N. Cost-effectiveness of dipeptidyl peptidase-4 inhibitor monotherapy versus sulfonylurea monotherapy for people with type 2 diabetes and chronic kidney disease in Thailand. J Med Econ. 2017;20(2):171\u201381.","journal-title":"J Med Econ"},{"issue":"1","key":"4980_CR37","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1186\/s12889-020-09387-w","volume":"20","author":"U Cha\u2019on","year":"2020","unstructured":"Cha\u2019on U, Wongtrangan K, Thinkhamrop B, Tatiyanupanwong S, Limwattananon C, Pongskul C, et al. CKDNET, a quality improvement project for prevention and reduction of chronic kidney disease in the Northeast Thailand. BMC Public Health. 2020;20(1):1299.","journal-title":"BMC Public Health"},{"issue":"21","key":"4980_CR38","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, K\u00f8ber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019;381(21):1995\u20132008.","journal-title":"N Engl J Med"},{"issue":"4","key":"4980_CR39","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019;380(4):347\u201357.","journal-title":"N Engl J Med"},{"issue":"4","key":"4980_CR40","doi-asserted-by":"publisher","first-page":"e475","DOI":"10.1097\/MD.0000000000000475","volume":"94","author":"P Vejakama","year":"2015","unstructured":"Vejakama P, Ingsathit A, Attia J, Thakkinstian A. Epidemiological study of chronic kidney disease progression: a large-scale population-based cohort study. Med (Baltim). 2015;94(4):e475.","journal-title":"Med (Baltim)"},{"issue":"1","key":"4980_CR41","first-page":"1","volume":"35","author":"N Thammatacharee","year":"2020","unstructured":"Thammatacharee N, Mills A, Nitsch D, Lumpaopong A. The changing patterns of access overtime to the renal replacement therapy programme in Thailand. Health Policy Plan. 2020;35(1):1\u20136.","journal-title":"Health Policy Plan"},{"issue":"2","key":"4980_CR42","doi-asserted-by":"publisher","first-page":"105","DOI":"10.63555\/jnst.2025.277563","volume":"31","author":"B Satirapoj","year":"2025","unstructured":"Satirapoj B, Tantiyavarong P, Chuasuwan A, Lumpaopong A, Limbutara K, Kiattilunthorn K, et al. Thailand Renal Replacement Therapy Registry 2023: Epidemiology and Trends in Incident Dialysis Patients. J Nephrol Soc Thail. 2025;31(2):105\u201322.","journal-title":"J Nephrol Soc Thail"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-026-04980-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-04980-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-04980-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T01:26:11Z","timestamp":1779758771000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12882-026-04980-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,14]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4980"],"URL":"https:\/\/doi.org\/10.1186\/s12882-026-04980-4","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,14]]},"assertion":[{"value":"6 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of Research, Faculty of Medicine Ramathibodi Hospital (COA-MURA2021\/522 and COA\u2010MURA2022\/474). The study was conducted following the Declaration of Helsinki. All authors declared no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"330"}}